Trial reportJournal of vascular surgery. Venous and lymphatic disorders2026
A randomized controlled trial of 3% polidocanol foam with saline prewashing compared with standard foam sclerotherapy for the treatment of varicose veins.
Trial report in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic venous disease is a highly prevalent global condition. Sclerotherapy with polidocanol foam is an established minimally invasive treatment. However, complications such as postprocedural hyperpigmentation remain common, and the maximum injectable volume per session may limit treatment efficacy. These factors highlight the need for optimized techniques to enhance vein occlusion and cosmetic outcomes. This study evaluated the efficacy and safety of 3% polidocanol foam with prewashing with saline compared with the conventional 1% polidocanol foam method.
methodsThis single-center, prospective, randomized controlled trial enrolled 35 patients (70 limbs) with Clinical Ethological Anatomical Pathophysiological class C2 to C5 varicose veins. Participants were randomized 1:1 to receive either 3% polidocanol foam with 0.9% saline prewashing and extrinsic compression using a low-density polyethylene cylinder at 20 to 30 mm Hg, or 1% polidocanol foam. Primary outcomes were venous occlusion at day 90 on Doppler ultrasound examination and foam volume. Secondary outcomes were superficial venous thrombosis, hyperpigmentation, and quality of life, assessed using the revised Venous Clinical Score at baseline and day 90.
resultsThirty-one patients (62 limbs) completed the study (16 in the 3% polidocanol plus saline prewashing group; 15 in the 1% polidocanol group). Baseline characteristics were comparable across treatment arms. No major adverse events occurred. Occlusion rates were similar between the groups (P = .80). The 3% polidocanol foam technique achieved comparable occlusion using significantly less foam volume (0.27 ± 0.21 mL vs 0.54 ± 0.28 mL; P < .001). Rates of superficial thrombosis and hyperpigmentation were low and did not differ significantly. No statistically significant difference in the revised Venous Clinical Score was observed between groups; the small sample size may limit interpretation of these findings.
conclusionsThe 3% SALFOAM method can be used with comparable efficacy and safety while using a lower sclerosant volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.